FDA issues warning over-the-counter diarrhea drug

(AP)—The Food and Drug Administration is warning consumers not to use an over-the-counter drug called Intestinomicina because the anti-diarrhea treatment contains a drug linked to life-threatening injuries.

The El Salvador-manufactured drug comes in pills and liquid forms and is sold as a treatment for at international grocery stores and specialty stores in the U.S.

Regulators say Intestinomicina contains the drug chloramphenicol, which can interfere with the production of red and . People with anemia and other low blood cell counts are at greater risk of injury or death from using the drug.

The FDA recalled all oral forms of chloramphenicol in July due to safety risks. The agency is asking consumers who purchased the product to stop taking it and consult a health care professional.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

US warns of drugs in Reumofan dietary supplements

Aug 21, 2012

(AP) — The U.S. Food and Drug Administration is warning consumers not to use Reumofan dietary supplements, after receiving reports of bleeding, stroke and death among Americans taking the Mexico-manufactured pills.

Perjeta approved for advanced breast cancer

Jun 11, 2012

(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Anemia drugs under scrutiny

Mar 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments